Clinical correlates of lifetime and current comorbidity patterns in autoimmune and inflammatory diseases

Signe Hässler,Roberta Lorenzon,Marie Binvignat,Claire Ribet,Alexandra Roux,Catherine Johanet,Chloé Amouyal,Serge Amselem,Francis Berenbaum,Olivier Benveniste,Patrice Cacoub,Gilles Grateau,Agnès Hartemann,David Saadoun,Joe-Elie Salem,Jérémie Sellam,Philippe Seksik,Eric Vicaut,Encarnita Mariotti-Ferrandiz,Michelle Rosenzwajg,David Klatzmann
DOI: https://doi.org/10.1016/j.jaut.2024.103318
2024-10-01
Abstract:Background: Autoimmune and inflammatory diseases (AIDs) are a heterogeneous group of disorders with diverse etiopathogenic mechanisms. This study explores the potential utility of family history, together with present and past comorbidities, in identifying distinct etiopathogenic subgroups. This approach may facilitate more accurate diagnosis, prognosis and personalized therapy. Methods: We performed a multiple correspondence analysis on patients' comorbidities, followed by hierarchical principal component clustering of clinical data from 48 healthy volunteers and 327 patients with at least one of 19 selected AIDs included in the TRANSIMMUNOM cross-sectional study. Results: We identified three distinct clusters characterized by: 1) the absence of comorbidities, 2) polyautoimmunity, and 3) polyinflammation. These clusters were further distinguished by specific comorbidities and biological parameters. Autoantibodies, allergies, and viral infections characterized the polyautoimmunity cluster, while older age, BMI, depression, cancer, hypertension, periodontal disease, and dyslipidemia characterized the polyinflammation cluster. Rheumatoid arthritis patients were distributed across all three clusters. They had higher DAS28 and prevalence of extra-articular manifestations when belonging to the polyinflammation and polyautoimmunity clusters, and also lower ACPA and RF seropositivity and higher pain scores within the polyinflammation cluster. We developed a model allowing to classify AID patients into comorbidity clusters. Conclusions: In this study, we have uncovered three distinct comorbidity profiles among AID patients. These profiles suggest the presence of distinct etiopathogenic mechanisms underlying these subgroups. Validation, longitudinal stability assessment, and exploration of their impact on therapy efficacy are needed for a comprehensive understanding of their potential role in personalized medicine.
What problem does this paper attempt to address?